Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15–23

Article  PubMed  PubMed Central  Google Scholar 

Reeves RA, Kaufman T (2024) Mammography. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing [cited 2024 Jan 23]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK559310/

Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48

Article  PubMed  Google Scholar 

da Costa Nunes GG, de Freitas LM, Monte N, Gellen LPA, Santos AP, de Moraes FCA et al (2024) Genomic variants and worldwide epidemiology of breast cancer: a genome-wide association studies correlation analysis. Genes (Basel) 15:145

Article  PubMed  Google Scholar 

de Moraes FCA, de Oliveira Almeida G, Alves VFC, Priantti JN, da Gomes GC, Carnevalli SVB et al (2024) Cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone for HR-positive, HER-2-negative early breast cancer: meta-analysis of phase III randomized clinical trials. J Pers Med. 14:464

Article  PubMed  PubMed Central  Google Scholar 

Health and Economic Benefits of Breast Cancer Interventions | Power of Prevention [Internet]. [cited 2024 Jan 23]. Available from: https://www.cdc.gov/chronicdisease/programs-impact/pop/breast-cancer.htm

Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A et al (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485:55–61

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paplomata E, O’Regan R (2014) The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol 6:154–166

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez-Angulo AM, Blumenschein GR (2013) Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39:313–320

Article  CAS  PubMed  Google Scholar 

Alzahrani AS (2019) PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol 59:125–132

Article  CAS  PubMed  Google Scholar 

Reuveni H, Livnah N, Geiger T, Klein S, Ohne O, Cohen I et al (2002) Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 41:10304–10314

Article  CAS  PubMed  Google Scholar 

Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y (2021) Targeting Akt in cancer for precision therapy. J Hematol Oncol 14:128

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martorana F, Motta G, Pavone G, Motta L, Stella S, Vitale SR et al (2021) AKT inhibitors: new weapons in the fight against breast cancer? Front Pharmacol 12:662232

Article  CAS  PubMed  PubMed Central  Google Scholar 

Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR et al (2013) Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. J Med Chem 56:2059–2073

Article  CAS  PubMed  Google Scholar 

Mattmann ME, Stoops SL, Lindsley CW (2011) Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin Ther Pat 21:1309–1338

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira M, Villagrasa P, Ciruelos E, Gavilá J, Cortegoso A, Henao F et al (2021) Abstract OT-35–01: Solti-1507 A phase ib study of ipatasertib and anti-her2 therapy in her2-positive advanced breast cancer with pik3ca mutation (ipather). Cancer Research. 81:OT-35-01

Article  Google Scholar 

Polivka J, Janku F (2014) Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142:164–175

Article  CAS  PubMed  Google Scholar 

Revathidevi S, Munirajan AK (2019) Akt in cancer: mediator and more. Semin Cancer Biol 59:80–91

Article  CAS  PubMed  Google Scholar 

Guerau-de-Arellano M, Piedra-Quintero ZL, Tsichlis PN (2022) Akt isoforms in the immune system. Front Immunol [Internet]. https://doi.org/10.3389/fimmu.2022.990874

Article  PubMed  Google Scholar 

Duronio V (2008) The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 415:333–344

Article  CAS  PubMed  Google Scholar 

Janku F, Yap TA, Meric-Bernstam F (2018) Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol 15:273–291

Article  CAS  PubMed  Google Scholar 

Coleman N, Moyers JT, Harbery A, Vivanco I, Yap TA (2021) Clinical development of AKT inhibitors and associated predictive biomarkers to guide patient treatment in cancer medicine. Pharmgenomics Pers Med 14:1517–1535

CAS  PubMed  PubMed Central  Google Scholar 

Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29–86

Article  CAS  PubMed  Google Scholar 

Wang Z, Yin G, Jia R (2019) Impacts of self-care education on adverse events and mental health related quality of life in breast cancer patients under chemotherapy. Complement Ther Med 43:165–169

Article  PubMed  Google Scholar 

Kamińska M, Ciszewski T, Kukiełka-Budny B, Kubiatowski T, Baczewska B, Makara-Studzińska M et al (2015) Life quality of women with breast cancer after mastectomy or breast conserving therapy treated with adjuvant chemotherapy. Ann Agric Environ Med 22:724–730

Article  PubMed  Google Scholar 

Szutowicz-Wydra B, Wydra J, Kruszewski WJ, Ciesielski M, Szajewski M, Walczak J et al (2016) Same quality of life for Polish breast cancer patients treated with mastectomy and breast reconstruction or breast-conserving therapy. Pol Przegl Chir 88:264–269

Article  PubMed  Google Scholar 

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed) 112:90–92. https://doi.org/10.1016/j.ad.2019.05.009

Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A et al (2019) Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res 21:78

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–47

Article  CAS  PubMed  Google Scholar 

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898

Article  PubMed  Google Scholar 

Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2024 Jan 23]. p. 205–28. https://doi.org/10.1002/9781119536604.ch8

IntHout J, Ioannidis JPA, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25

Article  PubMed  PubMed Central  Google Scholar 

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

Article